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The two MetaForum conferences provided an opportunity
for presentation of current information on asthma and
allergic rhinitis, as well as a forum for discussion by Euro-
pean experts of important issues in the field of allergy and
asthma [1]. Several key points were the focus of the talks
and discussions and led to the development of consensus
recommendations at the end of each conference. These
topics remain the focus of active investigation as well as
being very relevant today.
Results of epidemiologic studies indicate that allergic
rhinitis is a risk factor for asthma, that allergic rhinitis and
asthma often occur in association, and that having comor-
bid allergic rhinitis is a marker for the presence of more
difficult to control asthma and greater use of resources for
asthma [2]. Patients enrolled in the international survey
reported in the present supplement often experienced a
worsening of asthma symptoms when allergic rhinitis
symptoms worsened [3]. Moreover, inflammatory proc-
esses are very similar in asthma and allergic rhinitis [4].
These findings support the Allergic Rhinitis Impact on
Asthma recommendation that all patients with asthma be
checked for allergic rhinitis, and vice versa [5]. Treatment
plans need to take into account the presence of both con-
ditions. More generally, there is a need to promote the use
of combined therapies that are safe and effective for treat-
ing symptoms of both asthma and allergic rhinitis and
that address the inflammatory nature of these two condi-
tions affecting the 'one airway.' Active study continues to
better characterize the burden of comorbid asthma and
allergic rhinitis [6-8], as well as the potential benefits of
concomitantly treating both conditions [9].
The structured review of patient surveys reported in the
present supplement [10] suggests that asthma remains
poorly controlled for many adults and children. Patients
tolerate symptoms and have low expectations of asthma
treatment; communication between patients and their
physicians could be improved; and physicians often inac-
curately assess disease severity and asthma control.
Results of a recent review of pediatric studies worldwide
support these findings and suggest that asthma guidelines
are often not followed [11].
Better education of physicians about asthma and allergic
rhinitis and better communication between physicians
and patients are essential to improving asthma control.
The final paper of the present supplement examines
recent asthma guidelines and proposes possible ways in
which they could be improved [12]. Physicians need sim-
ple and practical tools to facilitate the diagnosis and
assessment of asthma in addition to identifying the fac-
tors responsible for poor control such as associated aller-
gic rhinitis, limited adherence, and smoking behavior. A
simple questionnaire to assess potential asthma symp-
toms in patients with allergic rhinitis has recently been
described [13]. Rapid dissemination of information about
such tools is needed once they have been developed and
validated.
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Finally, the development of country-specific guidelines or,
ideally, local guidelines for each region would provide
more practical solutions for asthma care and would
account for factors, such as social factors and costs, that
influence patient choice and adherence to therapy. These
issues require coordinated efforts between specialists in
the field and primary care physicians, as most medical
care for asthma and allergic rhinitis is delivered in a pri-
mary care setting.
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